关于召开 2024 年度股东会的通知（增加提案后） 共 6 页 证券代码：000931 证券简称：中关村 公告编号：2025-055 北京中关村科技发展（控股）股份有限公司 关于召开 2024 年度股东会的通知（增加提案后） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 北京中关村科技发展（控股）股份有限公司（以下简称：公司）已于 2025 年 4 月 18 日披露《关于召开 2024 年度股东会的通知》（公告编号：2025-046）。 2025 年 4 月 28 日，公司收到控股股东国美控股集团有限公司《关于北京 中关村科技发展（控股）股份有限公司 2024 年度股东会增加临时议案的提案函》， 决定将经公司第九届董事会 2025 年度第二次临时会议审议通过的《关于公司为 中实新材料向中国银行申请 1,000 万元融资授信提供担保的议案》《关于公司 为多多药业向中信银行申请 6,000 万元融资授信提供担保的议案》作为临时提 案，提交公司 2024 年度股东会审议。 现将增加临时提案后的 2024 年度股东会会议召开相关事宜通知如下： 一、召开会 ...

Group 1 - The company announced the establishment of a wholly-owned subsidiary, Jiangsu Huasu Hebei Technology Service Co., Ltd., with an investment of 1 million yuan [1] - The new subsidiary will focus on the technical development, promotion, transfer, consultation, and services related to daily chemicals, cosmetics, disinfectants, health products, and biological products [1] - The investment aims to enhance the product system, strengthen the production capacity of the Weihai production base, and diversify the product line to broaden revenue sources [1] Group 2 - The investment does not constitute a related party transaction or a major asset restructuring and does not require shareholder approval [1] - The company will actively implement strategies and management measures to address potential uncertainties associated with the investment [1] - The investment aligns with the company's strategic planning and business layout needs, and it will not significantly impact the company's financial status and operating results for the current year [1]

第九届董事会 2025 年度第二次临时会议决议公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-049 北京中关村科技发展（控股）股份有限公司 第九届董事会 2025 年度第二次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第九届董事 会 2025 年度第二次临时会议通知于 2025 年 4 月 22 日以专人送达、电子邮件或 传真等方式发出，会议于 2025 年 4 月 28 日上午 10 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场结合通讯表决方式如期召开。会议应到 董事 9 名，实到董事 9 名。会议召开程序符合相关法律法规和《公司章程》的有 关规定。经与会董事认真讨论研究，形成以下决议： 一、审议通过《2025 年第一季度报告》； 表决结果：9 票同意，0 票反对，0 票弃权。 《2025 年第一季度财务报表》已经董事会审计委员会审议通过。 具体内容详见与本公告同日披露的《2025 年第一季度报告》（公告编号： 2 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 616,290,632.44, representing a 1.63% increase compared to CNY 606,418,745.97 in the same period last year[5]. - Net profit attributable to shareholders increased by 35.47% to CNY 15,756,417.46 from CNY 11,631,055.35 year-on-year[5]. - The net profit after deducting non-recurring gains and losses surged by 124.92% to CNY 14,859,606.87 compared to CNY 6,606,701.04 in the previous year[5]. - The basic earnings per share increased by 35.71% to CNY 0.0209 from CNY 0.0154 in the previous year[5]. - Net profit for the current period was ¥18,569,461.39, up from ¥12,221,608.41 in the previous period, indicating a growth of approximately 52.1%[41]. - The company reported a basic and diluted earnings per share of ¥0.0209, compared to ¥0.0154 in the previous period, marking an increase of 35.7%[42]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 3,763,967,569.81, a 1.40% increase from CNY 3,712,072,946.95 at the end of the previous year[5]. - Total current assets increased to ¥1,694,347,602.60 from ¥1,608,572,076.75, showing a growth of about 5.34%[37]. - Total liabilities rose to ¥1,938,376,781.22 from ¥1,905,075,191.42, reflecting an increase of approximately 1.73%[38]. - Non-current assets decreased slightly to ¥2,069,619,967.21 from ¥2,103,500,870.20, a decline of about 1.61%[37]. - The company’s total equity increased to ¥1,825,590,788.59 from ¥1,806,997,755.53, reflecting a growth of about 1.03%[38]. Cash Flow - The net cash flow from operating activities decreased by 13.08% to CNY 65,817,386.44 from CNY 75,724,156.95 year-on-year[5]. - Operating cash inflow for the current period was CNY 661,698,263.65, an increase of 3.1% from CNY 638,384,479.19 in the previous period[43]. - Net cash flow from operating activities decreased to CNY 65,817,386.44, down 13.1% from CNY 75,724,156.95 in the previous period[43]. - Cash outflow from investment activities was CNY 27,129,815.36, a decrease of 13.5% compared to CNY 31,481,850.94 in the previous period[44]. - Net cash flow from financing activities improved to CNY 8,349,308.14, compared to a net outflow of CNY 19,602,920.60 in the previous period[44]. - The net increase in cash and cash equivalents for the current period was CNY 47,549,946.22, up 92.1% from CNY 24,702,423.76 in the previous period[44]. - The ending balance of cash and cash equivalents was CNY 186,333,958.00, down from CNY 210,575,158.90 in the previous period[44]. Shareholder Information - The company reported a total of 70,713 common shareholders at the end of the reporting period[12]. - The largest unrestricted shareholders are Gome Holdings Group Co., Ltd. with 186,113,207 shares and Gome Electrical Appliances Co., Ltd. with 50,807,055 shares[13]. - Gome Holdings Group's frozen shares include 12,500,000 shares judicially frozen, 110,403,529 shares judicially re-frozen, and 59,562,814 shares under pending freeze[14]. - Gome Holdings Group Co., Ltd. holds 186,113,207 shares, representing 24.71% of total shares[21]. - Gome Electrical Appliances Co., Ltd. holds 50,807,055 shares, representing 6.75% of total shares[21]. - A total of 236,920,262 shares are held by major shareholders, accounting for 31.46% of total shares[21]. - Gome Holdings has pledged 111,601,400 shares, which is 59.96% of its holdings[21]. - Gome Holdings has 122,903,529 shares under judicial freeze, representing 66.04% of its holdings[22]. - Gome Electrical Appliances has 50,807,055 shares under judicial freeze, accounting for 100% of its holdings[22]. Corporate Governance - The company held its first temporary shareholders' meeting on January 23, 2025, to elect the ninth board of directors and supervisory board[16]. - The ninth board of directors consists of 6 non-independent directors and 3 independent directors, with Xu Zhongmin as the chairman[17]. - The audit committee is chaired by Bi Ke, a professional accountant, with members including Huang Xiuhong, Shi Lu Wen, and Xia Qin[17]. - The company appointed Hou Zhanjun as the president and several others as vice presidents, with their terms aligned with the current board[17]. - Lin Feiyan has terminated the concerted action agreement with Gome Holdings and Gome Electrical Appliances[19]. - The shareholding ratio of the controlling shareholder and its concerted parties changed following the termination of the agreement[19]. Subsidiary Developments - The company’s subsidiary, Beijing Huasu Pharmaceutical, received acceptance for the consistency evaluation of Tramadol Hydrochloride Tablets[24]. - The company’s subsidiary, Duoduo Pharmaceutical, won the bid for the national centralized procurement of Siberian Ginseng Injection at a price of 13.18 yuan per unit[25]. - The procurement cycle for the selected product is from the execution date until December 31, 2027[25]. - Beijing Huasu Pharmaceutical's raw material drug, Benzydamine, has received the production license and passed the GMP compliance inspection, indicating it meets current drug management standards and can ensure patient safety[27][28][29]. - Beijing Zhongshi New Materials has been awarded the High-tech Enterprise Certificate, valid for three years, allowing it to benefit from a 15% corporate income tax rate from 2024 to 2026[30]. - Shandong Huasu Health Care Products has also received the High-tech Enterprise Certificate, which is expected to positively impact the company's performance in 2024[31]. - Beijing Huasu's application for the marketing license of Oxycodone Hydrochloride Controlled-release Tablets (40mg) has been accepted, marking the start of the review phase[32][33]. - Duoduo Pharmaceutical's application for the marketing license of Bromhexine Hydrochloride Injection (2ml:4mg) has been accepted, indicating progress in the development of respiratory medications[34]. Operational Efficiency - The company has optimized its production structure and expanded its product range, enhancing its core competitiveness and meeting market demand[29]. - The acceptance of multiple drug applications is expected to enhance the company's market competitiveness and positively impact its financial performance[33][34]. Other Financial Metrics - Total operating revenue for the current period reached ¥616,290,632.44, an increase from ¥606,418,745.97 in the previous period, representing a growth of approximately 1.43%[40]. - Total operating costs decreased to ¥591,018,803.44 from ¥594,281,237.26, reflecting a reduction of about 0.38%[40]. - Research and development expenses were reported at ¥16,977,265.67, down from ¥22,994,485.44, indicating a decrease of approximately 26%[41]. - The company’s cash and cash equivalents were not explicitly detailed, but the increase in current assets suggests improved liquidity[37]. - The company’s first quarter report was not audited[46].

Core Viewpoint - The company Zhongguancun (000931) experienced a decline in stock price, with a closing price of 4.56 yuan, down 6.75% as of April 28, 2025, indicating a significant outflow of funds from major investors [1]. Financial Performance - For the fiscal year ending 2024, Zhongguancun reported total revenue of 2.532 billion yuan, representing a year-on-year growth of 11.22% - The net profit attributable to shareholders was 53.5922 million yuan, showing a year-on-year increase of 10.33% - The company's non-recurring net profit was 32.6895 million yuan, which reflects a year-on-year decrease of 7.54% - Key financial ratios include a current ratio of 1.166, a quick ratio of 1.011, and a debt-to-asset ratio of 51.32% [1]. Market Activity - The stock had a turnover rate of 4.05%, with a trading volume of 302,100 hands and a transaction amount of 140 million yuan - Major funds saw a net outflow of 35.2605 million yuan, accounting for 25.11% of the transaction amount, with large orders contributing to a significant portion of this outflow [1]. Company Background - Zhongguancun Technology Development (Holding) Co., Ltd. was established in 1999 and is based in Beijing, primarily engaged in the business services industry - The company has a registered capital of 753.126982 million yuan, which is also its paid-in capital, and is represented legally by Xu Zhongmin [2]. Investment and Intellectual Property - The company has made investments in 24 enterprises and participated in six bidding projects - It holds 139 trademark registrations and possesses 10 administrative licenses [2].

注：专利权自授权公告之日起生效。专利权期限为十年，自申请日起算。 关于下属公司山东华素健康护理品公司取得实用新型专利证书的公告 共 1 页 证券代码：000931 证券简称：中关村 公告编号：2025-048 北京中关村科技发展（控股）股份有限公司 关于下属公司山东华素健康护理品公司取得实用新型 专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属 公司山东华素健康护理品有限公司取得国家知识产权局颁发的实用新型专利证 书，具体情况如下： | 实用新型名称 | 专利申请日 | | | | 授权公告日 | | | 专利号 | 授权公告号 | 专利权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 一种牙膏泡沫 | 2024 05 | 年 | 月 | 24 | 年 月 2025 25 | 04 | 日 | ZL 2024 2 | CN | 山东华素健康护 | | 量罗氏测定仪 | 日 | | ...

转自：北京日报客户端 4月24日至25日，"中关村生命健康产业创新大会（昌黎·2025）"在河北省秦皇岛市昌黎举办。大会 以"共启京冀合作新征程 共谋健康产业新发展"为主题，通过实地考察、专题研讨、战略签约等形式， 共绘昌黎生命健康产业发展蓝图。会上，中关村医疗器械成果转化平台昌黎分中心正式揭牌。 创新大会 活动现场。主办方供图 4月24日，与会嘉宾实地参观了中关村生命园昌黎科创基地，深入了解昌黎生命健康产业规划与建设进 展，并进行了座谈交流。4月25日，大会通过领导致辞、主题报告、揭牌签约、圆桌研讨等环节全面推 动合作落地。 据悉，"中关村医疗器械成果转化平台昌黎分中心"正式揭牌，围绕分中心，公共服务平台、产业升级、 医疗器械销售及投资项目等实现集中签约，涉及20余家知名企业。中关村医疗器械成果转化平台是中关 村发展集团在医疗器械领域的科技成果转化专业化服务平台。中关村医疗器械成果转化平台（昌黎分中 心）将借助中关村专业化服务，极大促进昌黎医疗器械成果加速转化。 在集中签约中，公共服务平台项目汇聚杰诺医学、北京大学口腔医学院检验中心等5家机构，将构建"研 发-检测-转化-供应链"全链条服务体系；传统产业升级 ...

其中，即日起至27日，北京卫星制造厂科技园将变身"航天主题乐园"。15家航天科技企业、10家科技文 化创意机构联袂打造互动市集，设置"太空宇宙飞船基地""航天相关物品陈列区""宇宙护照集章"等五大 沉浸式体验区。游客可近距离接触航天模型、体验脑机接口技术、参与AI编程挑战，还能与"宇航员"互 动打卡，感受航天科技的魅力。 转自：北京日报客户端 4月24日，"海淀区航天日主题活动暨中关村地区科技文化季启动仪式"在位于海淀区中关村街道的"两弹 一星"海淀主题展馆举行，"中关村地区科技文化季"系列活动现场发布。 据了解，本次科技文化季涵盖"探索无垠空间，激发科技未来"航空航天科技节、"揽星逐光·星河新 篇"纪念"东方红一号"卫星发射55周年主题特展、"探寻AI的进化革新之路"、"AI赋能未来城市——社会 治理的智慧跃迁"科普实践等6大分支的10个主题项目，打造全民参与的科技文化盛宴。 此外，8月实施的"智慧治理解码"项目将聚焦AI在社会治理中的创新应用。据悉，专家团队将通过模拟 实操与案例解析，直观展现AI在交通优化、生态监测、公共安全等领域的治理效能。特别设置的伦理 思辨环节，将引导公众探讨技术边界与人文关怀的平 ...

北京商报讯（记者 金朝力）4月24日，是东方红一号卫星成功发射55周年纪念日及第10个中国航天日。 为弘扬"两弹一星"精神，提升海淀区科技文化品牌影响力，当天上午，海淀区航天日主题活动暨中关村 地区科技文化季系列活动在"两弹一星"在海淀主题展馆内拉开帷幕。 本次活动由中共北京市海淀区委宣传部、中关村街道党工委、中关村街道办事处主办，北京市海淀区文 化发展促进中心、北京海新域城市更新集团有限公司承办，海淀区文学艺术界联合会、海淀区人才工作 局、中关村科学城管委会、海淀区文化和旅游局、海淀区科学技术协会协办。 活动现场，中关村街道党工委书记董智杭介绍了"中关村地区科技文化季"系列活动的精彩内容，活动将 通过构建"航空航天科技节+艺术嘉年华+科创研学教育+街巷文化计划+主题展览"等多维联动传播体 系，在公众与航天事业间架设精神桥梁，既点燃全民科学热情，更推动科技元素与人文情怀深度交融， 为北京国际科技创新中心注入文化动能。同时中关村街道副主任黄宇玲强调，要以此次活动为契机，将 航天精神融入区域发展血脉，以'硬科技+软表达'的双轮驱动模式，让科技与文化在融合中迸发出全新 的活力，更好地肩负起国家创新驱动发展战略的重要 ...

Product Overview - The company focuses on key narcotic products, including the oxycodone series and the new drug dihydroetorphine sublingual tablets, with a comprehensive product cluster in the analgesic field [3] - The core products include oxycodone raw materials and formulations, as well as tramadol series products from subsidiary companies [3] Sales Growth and Market Potential - The sales revenue of oxycodone injection is expected to exceed 100% growth in 2025, driven by increasing market demand in various medical fields [4] - The domestic sales of oxycodone products reached CNY 1.907 billion in 2024, with the company aiming to capture a significant market share [5] R&D Progress and Future Plans - The company is developing methylphenidate products, with the chewable tablets and oral suspension currently in the development stage [6] - A collaboration with a military research institute aims to enhance the R&D capabilities for methylphenidate products [6] - The market for methylphenidate is promising, with a projected sales revenue of CNY 526 million in 2024 [7] Strategic Product Pipeline - The company is expanding its narcotic product line, with several products in different stages of development, including oxycodone sustained-release tablets [8] - The strategic layout includes a focus on chronic disease management, narcotic specialties, and mental health products [9] Market Trends and Challenges - The demand for antihypertensive drugs is expected to grow due to an aging population and younger patients with hypertension [10] - The potential for the company's flagship product, Yuanzhi, to be included in national drug procurement policies is acknowledged, with strategies in place to mitigate impacts [10]